Know Cancer

forgot password

A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma

Phase 3
18 Years
Open (Enrolling)
Metastatic Renal Cell Carcinoma

Thank you

Trial Information

A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma

This is a multicenter, open-label, randomized phase III study to investigate whether
therapeutic vaccination with IMA901, a mult-peptide cancer vaccine (TUMAP), can prolong
overall survival in patients with metastatic and/or locally advanced RCC when added to
standard first-line therapy with sunitinib (primary endpoint).

Secondary endpoints include a subgroup analysis of overall survival in patients who are
positive for a prospectively defined primary biomarker signature (identified as being
predictive for improved clinical outcome in IMA901-vaccinated patients in the previous phase
II study), progression-free survival (PFS), best overall response, cellular immunomonitoring
in a subset of patients, and safety. Safety analysis will be based on adverse events (AEs),
physical examinations, vital signs, hematology, clinical chemistry, urinalysis and ECG

Further endpoints include subgroup analyses of overall survival in patients who are positive
for further prospectively defined biomarkers (identified in the previous phase II study),
and exploratory screening of new biomarkers (to be investigated in patients' blood and
paraffin sections from tumor tissue) to predict better clinical outcome as response to
vaccination with IMA901. Biomarker sets will not be used for patient selection in this

Inclusion Criteria:

1. Aged at least 18 years.

2. HLA type: HLA-A*02-positive

3. Metastatic and/or locally advanced RCC with clear cell histology (histological
confirmation by local pathologist required). NOTE: prior nephrectomy is NOT required.

4. Measurable and/or non-measurable tumor lesions as per RECIST 1.1

5. Patients who are candidates for a first-line therapy with sunitinib.

6. Favorable or intermediate risk according to the 6-score risk criteria in patients
treated with VEGF-targeted agents according to Heng [Heng et al. 2009]. The patient
has a favorable risk if none, or intermediate risk if one or two of the following
criteria apply (if three or more criteria apply the patient is not eligible):

1. Hemoglobin < LLN,

2. Serum corrected calcium > ULN,

3. Karnofsky performance status < 80%,

4. Time from initial diagnosis to initiation of therapy < 1 year,

5. Absolute neutrophil count > ULN,

6. Platelets > ULN.

7. Able to understand the nature of the study and give written informed consent.

8. Willingness and ability to comply with the study protocol for the duration of the

9. Female patients who are post menopausal (no menstrual period for a minimum of 1
year), or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
hysterectomy) or practice a medically acceptable method of birth control.

10. Male patients willing to use contraception (upon study entry and during the course of
the study or have undergone vasectomy.

Exclusion Criteria:

1. Prior systemic therapy for metastatic disease. (Note: prior adjuvant treatment for
non-metastatic disease is allowed, however adjuvant therapy must have been stopped ≥
1 year before Visit C).

2. History of or current brain metastases.

3. Abnormal ≥ CTC Grade 3 laboratory values for hematology (Hb, WBC, neutrophils,
lymphocytes, platelets), liver (serum bilirubin, ALAT or ASAT) and renal function
(serum creatinine).

4. Metastatic second malignancy.

5. Localized second malignancy expected to influence the patient's life span.

6. Patients with a history or evidence of systemic autoimmune disease, e.g., rheumatoid
arthritis, multiple sclerosis, systemic lupus erythematodes (SLE), scleroderma,
Sjögren's syndrome, Wegener's granulomatosis, Guillain-Barre syndrome.

7. Known active hepatitis B or C infection.

8. Known HIV infection.

9. Active infections requiring oral or intravenous antibiotics.

10. Any other known infection with a biological agent that can cause a severe disease and
poses a severe danger to lab personnel working on patients' blood or tissue.

11. Received study drug within any clinical study (including approved and experimental
drugs) within 4 weeks before sunitinib start.

12. Serious intercurrent illness, which according to the investigator, poses an undue
risk for the patient when participating in the trial, including, but not limited to,
any of the following:

- Clinically significant cardiovascular disease (e.g., uncontrolled hypertension;
clinically significant cardiac arrhythmia, clinically significant

- New York Heart Association class III-IV congestive heart failure,

- Symptomatic peripheral vascular disease,

- Severe pulmonary dysfunction,

- Psychiatric illness or social situation that would preclude study compliance.

13. Less than 12 months since any of the following:

- Myocardial infarction,

- Severe or unstable angina,

- Coronary or peripheral artery bypass graft,

- Cerebrovascular event incl. transient ischemic attack,

- Pulmonary embolism / deep vein thrombosis (DVT).

14. Pregnancy or breastfeeding.

15. Any condition which in the judgment of the investigator would place the patient at
undue risk or interfere with the results of the study.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall survival

Outcome Time Frame:

2015 (estimated)

Safety Issue:


Principal Investigator

Brian Rini, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cleveland Clinic Taussig Cancer Institute


France: Agence Nationale de Sécurité du Médicament et des produits de santé

Study ID:




Start Date:

December 2010

Completion Date:

April 2015

Related Keywords:

  • Metastatic Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma
  • First line
  • Eligible for sunitinib
  • Carcinoma
  • Carcinoma, Renal Cell



Vanderbilt-Ingram Cancer Center Nashville, Tennessee  37232-6838
University of Arkansas for Medical Sciences Little Rock, Arkansas  72205
Seattle Cancer Care Alliance Seattle, Washington  98109
IU Simon Cancer Center Indianapolis, Indiana  46202
Karmanos Cancer Institute Detroit, Michigan  48201
University of Cincinnati Cincinnati, Ohio  45267-0502
Georgetown University Medical Center, Lombardi Comprehensive Cancer Center Washington, District of Columbia  20007
Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio  44195
Cedars-Siani Medical Center, Samuel Oschin Comprehensive Cancer Institute Los Angeles, California  90048
Kaiser Permanente Oncology Hematology Clinic Denver, Colorado  80205
M.D. Anderson Cancer Center Orlando, Florida  32806
Fred C. Buffett Professor of Medicine & Surgery Sections Hematology/Oncology & Urology University of Chicago Chicago, Illinois  60637
North Central Cancer Treatment Group, Illinois Cancer Care Peoria, Illinois  61615-7822
Weinberg Cancer Institute at Franklin Hospital Baltimore, Maryland  21237
Clinical Research Alliance Lake Success, New York  11042
UPMC Cancer Pavilion, University of Pittsburgh Cancer Institute, Division of Hematology / Oncology Pittsburgh, Pennsylvania  15232
South Texas Oncology & Hematology, P.A., The Start Center For Cancer Care San Antonio, Texas  78229